(1.38%) 5 133.90 points
(1.30%) 38 724 points
(2.15%) 16 182 points
(-1.03%) $78.14
(5.06%) $2.14
(-0.02%) $2 309.10
(-0.60%) $26.67
(0.21%) $964.65
(-0.37%) $0.929
(-1.18%) $10.86
(-0.14%) $0.797
(0.38%) $91.48
1.97% $ 2.85
@ $3.72
Emitido: 14 feb 2024 @ 11:00
Retorno: -23.52%
Señal anterior: feb 13 - 15:15
Señal anterior:
Retorno: 1.36 %
Live Chart Being Loaded With Signals
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC)...
Stats | |
---|---|
Volumen de hoy | 371 875 |
Volumen promedio | 766 514 |
Capitalización de mercado | 274.51M |
EPS | $0 ( 2024-03-14 ) |
Próxima fecha de ganancias | ( $-0.340 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.08 |
ATR14 | $0.00600 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 250 000 | Employee Stock Option (Right to Buy) |
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 185 000 | Common Stock |
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 0 | |
2024-03-01 | Mylet Johanna | Buy | 80 743 | Common Stock |
2024-03-01 | Mylet Johanna | Sell | 18 091 | Common Stock |
INSIDER POWER |
---|
88.71 |
Last 92 transactions |
Buy: 9 056 534 | Sell: 550 582 |
Volumen Correlación
Poseida Therapeutics, Correlación
10 Correlaciones Más Positivas | |
---|---|
EUSGU | 0.901 |
CVCY | 0.897 |
AGNCM | 0.884 |
MTRX | 0.88 |
RING | 0.879 |
TBNK | 0.877 |
DOOO | 0.875 |
VIOT | 0.873 |
WINC | 0.865 |
GTH | 0.862 |
10 Correlaciones Más Negativas | |
---|---|
PPTA | -0.858 |
FAIL | -0.85 |
AMRK | -0.842 |
SABRP | -0.832 |
HYMC | -0.827 |
LLNW | -0.825 |
PAAS | -0.812 |
MBCN | -0.81 |
GALT | -0.808 |
STAA | -0.805 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Poseida Therapeutics, Correlación - Moneda/Commodity
Poseida Therapeutics, Finanzas
Annual | 2023 |
Ingresos: | $64.70M |
Beneficio Bruto: | $64.70M (100.00 %) |
EPS: | $-1.370 |
FY | 2023 |
Ingresos: | $64.70M |
Beneficio Bruto: | $64.70M (100.00 %) |
EPS: | $-1.370 |
FY | 2022 |
Ingresos: | $130.36M |
Beneficio Bruto: | $125.19M (96.03 %) |
EPS: | $-0.890 |
FY | 2021 |
Ingresos: | $31 238.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.00201 |
Financial Reports:
No articles found.
Poseida Therapeutics,
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico